SCHEMBL5315577

SCHEMBL5315577

CNC(=O)NCCN(CC(=O)Nc1ccc(Oc2ccccc2)cc1)C1CCN(Cc2ccc(C(=O)O)cc2)CC1

nearest known ligand 0.71

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 17/20 0.71
CHRM4 P08173 1/20 0.53
MCHR2 Q969V1 1/20 0.48
MCHR1 Q99705 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5330282 0.88 LTA4H (0.79) LTA4H
SCHEMBL5312127 0.87 LTA4H (0.75) LTA4H
SCHEMBL5313293 0.87 LTA4H (0.75) LTA4HCHRM4
SCHEMBL5313842 0.87 LTA4H (0.80) LTA4H
SCHEMBL5315406 0.85 LTA4H (0.77) LTA4HCHRM4
SCHEMBL5313780 0.85 LTA4H (0.71) LTA4HCHRM4
SCHEMBL5309952 0.84 LTA4H (0.76) LTA4HCHRM4
SCHEMBL5313205 0.83 LTA4H (1.00) LTA4H
SCHEMBL5313965 0.82 LTA4H (0.81) LTA4HCHRM4
SCHEMBL5314354 0.81 LTA4H (0.80) LTA4HCHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007079003-A2 AMIDE INHIBITORS OF LEUKOTRIENE A4 HYDROLASE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-07-12 WO disclosed
US-20070155727-A1 Amide inhibitors of leukotriene A4 hydrolase SCHERING AKTIENGESSELLSCHAFT (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155727-A1 Amide inhibitors of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S LTA4H 1/4885CHRM4 213/4885MCHR2 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.